Press Releases CureVac N.V. Deutsche Boerse AG

Equities

5CV

NL0015436031

Market Closed - Deutsche Boerse AG Other stock markets 03:19:57 2024-05-17 pm EDT			5-day change	1st Jan Change
3.186 ^EUR	+1.14%		+17.13%	-17.03%

May. 02	CUREVAC : A missed opportunity
Apr. 26	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza Development in Collaboration with GSK	Apr. 25	AQ
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update	Apr. 24	EQ
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK	Apr. 24	EQ
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer	Apr. 24	EQ
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024	Apr. 18	EQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 17	AQ
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines	Apr. 16	EQ
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK	Apr. 04	EQ
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform	Jan. 05	EQ
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE	Dec. 20	AQ
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE	Dec. 19	EQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K	Nov. 14	PU
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update	Nov. 14	EQ
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK	Nov. 01	EQ
CureVac N : to Report Third Quarter and First Nine Months 2023 Financial Results and Business Updates on November 14, 2023	23-10-31	PU
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany	23-09-28	EQ
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage	23-09-12	EQ
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update	23-08-18	AQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - Form 6-K	23-08-17	PU
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update	23-08-17	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : A missed opportunity

May 02, 2024 at 05:42 pm EDT